Technology Listings


hPSC-Derived Endothelial Cell Generation System

Application

Clinically compatible cell culture system to generate endothelial cells (EC) from human pluripotent stem cells (hPSC).

Key Benefits
  • Produces hPSC-ECs in high yield.
  • Compatible with clinical applications of hPSC-derived endothelial cells.
  • Engrafted cells survive longer (>10 months) than in prior published research (weeks).
Market Summary

According to the World Health Organization (WHO), cardiovascular diseases (CVD) are the most common causes of death globally. CVDs such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease can cause loss of vascular supply, or ischemia. Ischemia causes loss of oxygen needed for cell function and leads to cell dysfunction and cell death. Therapies that promote growth of blood vessels are necessary to mitigate ischemic damage. Human pluripotent stem cells (hPSC) are a promising source for generating endothelial cells (EC), which play a crucial role in blood vessel growth and function.

Technical Summary

hPSC-derived endothelial cell (EC) therapies are limited by the need for a clinically compatible system that is free of xenogeneic components, has high functional EC yield, can be verified in multiple cell lines, and has no tumorigenic potential. Emory inventors developed a cell culture system to generate purified, functional EC with pro-angiogenic properties. These cells express EC factors CDH5, Von Willebrand factor, and KDR. Engineered EC also produce nitric oxide and form vascular-like structures. This cell culture system was found to increases EC marker expression in three human embryonic stem cell (hESC) lines and in two human induced pluripotent stem cell (hiPSC) lines. When injected into mice, hPSC-derived EC incorporated into blood vessels over time and were not found to form tumors.

Developmental Stage

This system has been tested in vitro and in vivo.

Publications: Lee, S. et. al. (2017). Circulation,136(20), 1939-1954.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Utility(parent) United States 15/805,894 11/7/2017     Pending
Tech ID: 16145
Published: 12/11/2017
Category
Therapeutics

Contact
John Nicosia
Licensing Associate
Emory University
404-727-0057
jnicosi@emory.edu

Inventor(s)
Young-Sup Yoon
Shin-Jeong Lee
Ho-Wook Jun

Keywords
Cardiovascular
Cell/Gene Therapy